glp 1 analog GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways GLP-1 Synthetic Peptide Analog |
Description
Further research is warranted to explore long-term outcomes and optimize treatment protocols for this patient population
Theyre treating real diseases that affect millions of people, but theyre not the growth story anymore
The reason
Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors can reduce CV risk in patients with T2D, and both are recommended by the American Diabetes Association to reduce the risk of major cardiovascular events (MACE)
Background: The evidence on berberine stimulating the secretion of GLP-1 in intestinal L cell has been studied
Recently, the introduction of highly effective glucagon-like peptide-1 (GLP-1) receptor agonists has led to increased utilization of obesity medications in this population
